{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:17:27Z","timestamp":1791839847509,"version":"4.3.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Diverse signalling pathways are involved in carcinogenesis and one of such pathways implicated in many cancers is the interleukin 6\/signal transducer and activator of transcription 3 (IL-6\/STAT3) signalling pathway. Therefore, inhibition of this pathway is targeted as an anti-cancer intervention. This study aimed to establish the effect of cryptolepine, which is the main bioactive alkaloid in the medicinal plant<jats:italic>Cryptolepis sanguinolenta<\/jats:italic>, on the IL-6\/STAT3 signalling pathway.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>First, the effect of cryptolepine on the IL-6\/STAT3 pathway in human hepatoma cells (HepG2 cells) was screened using the Cignal Finder Multi-Pathway Reporter Array. Next, to confirm the effect of cryptolepine on the IL-6\/STAT3 signalling pathway, the pathway was activated using 200\u2009ng\/mL IL-6 in the presence of 0.5\u20132\u2009\u03bcM cryptolepine. The levels of total STAT3, p-STAT3 and IL-23 were assessed by ELISA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Cryptolepine downregulated 12 signalling pathways including the IL-6\/STAT3 signalling pathway and upregulated 17 signalling pathways. Cryptolepine, in the presence of IL-6, decreased the levels of p-STAT3 and IL-23 in a dose-dependent fashion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results demonstrated that cryptolepine inhibits the IL-6\/STAT3 signalling pathway, and therefore cryptolepine-based remedies such as<jats:italic>Cryptolepis sanguinolenta<\/jats:italic>could potentially be used as an effective immunotherapeutic agent for hepatocellular carcinoma and other cancers.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12906-021-03326-x","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T06:06:15Z","timestamp":1622613975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cryptolepine inhibits hepatocellular carcinoma growth through inhibiting interleukin-6\/STAT3 signalling"],"prefix":"10.1186","volume":"21","author":[{"given":"Seth A.","family":"Domfeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Narkwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osbourne","family":"Quaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwadwo A.","family":"Kusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon A.","family":"Awandare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Ansah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alimatu","family":"Salam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Mutocheluh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"issue":"23","key":"3326_CR1","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.1158\/1078-0432.CCR-17-1283","volume":"23","author":"Y Yin","year":"2017","unstructured":"Yin Y, Yao S, Hu Y, Feng Y, Li M, Bian Z, et al. The immune-microenvironment confers chemoresistance of colorectal cancer through macrophage-derived IL-6. Clin Cancer Res. 2017;23(23):7375\u201387. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1283.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3326_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/21623945.2020.1814545","volume":"9","author":"B Feng","year":"2020","unstructured":"Feng B, Zhu Y, Yan L, Yan H, Huang X, Jiang D, et al. Ursolic acid induces the production of IL-6 and chemokines in both adipocytes and adipose tissue. Adipocyte. 2020;9(1):523\u201334. https:\/\/doi.org\/10.1080\/21623945.2020.1814545.","journal-title":"Adipocyte"},{"issue":"2","key":"3326_CR3","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/cancers6020897","volume":"6","author":"RL Carpenter","year":"2014","unstructured":"Carpenter RL, Lo H-W. STAT3 target genes relevant to human cancers. Cancers. 2014;6(2):897\u2013925. https:\/\/doi.org\/10.3390\/cancers6020897.","journal-title":"Cancers"},{"issue":"6","key":"3326_CR4","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1002\/hep.30774","volume":"70","author":"N Fazel Modares","year":"2019","unstructured":"Fazel Modares N, Polz R, Haghighi F, Lamertz L, Behnke K, Zhuang Y, et al. IL-6 trans-signalling controls liver regeneration after partial hepatectomy. Hepatology. 2019;70(6):2075\u201391. https:\/\/doi.org\/10.1002\/hep.30774.","journal-title":"Hepatology"},{"issue":"1","key":"3326_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1152\/ajpgi.00097.2018","volume":"316","author":"WT Peppler","year":"2019","unstructured":"Peppler WT, et al. Acute administration of IL-6 improves indices of hepatic glucose and insulin homeostasis in lean and obese mice. Am J Physiology-Gastrointestinal Liver Physiol. 2019;316(1):166\u201378.","journal-title":"Am J Physiology-Gastrointestinal Liver Physiol"},{"issue":"1","key":"3326_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-016-0009-6","volume":"8","author":"M Zhou","year":"2017","unstructured":"Zhou M, et al. Non-cell-autonomous activation of IL-6\/STAT3 signalling mediates FGF19-driven hepatocarcinogenesis. Nat Commun. 2017;8(1):1\u201316.","journal-title":"Nat Commun"},{"issue":"3","key":"3326_CR7","doi-asserted-by":"publisher","first-page":"570","DOI":"10.7150\/jca.35631","volume":"11","author":"X Gai","year":"2020","unstructured":"Gai X, Zhou P, Xu M, Liu Z, Zheng X, Liu Q. Hyperactivation of IL-6\/STAT3 pathway leaded to the poor prognosis of post-TACE HCCs by HIF-1\u03b1\/SNAI1 axis-induced epithelial to mesenchymal transition. J Cancer. 2020;11(3):570\u201382. https:\/\/doi.org\/10.7150\/jca.35631.","journal-title":"J Cancer"},{"issue":"40","key":"3326_CR8","doi-asserted-by":"publisher","first-page":"69139","DOI":"10.18632\/oncotarget.19932","volume":"8","author":"P Gao","year":"2017","unstructured":"Gao P, Niu N, Wei T, Tozawa H, Chen X, Zhang C, et al. The roles of signal transducer and activator of transcription factor 3 in tumour angiogenesis. Oncotarget. 2017;8(40):69139\u201361. https:\/\/doi.org\/10.18632\/oncotarget.19932.","journal-title":"Oncotarget"},{"issue":"4","key":"3326_CR9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/carcin\/bgv017","volume":"36","author":"H Liu","year":"2015","unstructured":"Liu H, Ren G, Wang T, Chen Y, Gong C, Bai Y, et al. Aberrantly expressed Fra-1 by IL-6\/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition. Carcinogenesis. 2015;36(4):459\u201368. https:\/\/doi.org\/10.1093\/carcin\/bgv017.","journal-title":"Carcinogenesis"},{"issue":"4","key":"3326_CR10","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/stem.2320","volume":"34","author":"C Yao","year":"2016","unstructured":"Yao C, Su L, Shan J, Zhu C, Liu L, Liu C, et al. IGF\/STAT3\/NANOG\/slug signalling axis simultaneously controls epithelial-mesenchymal transition and stemness maintenance in colorectal cancer. Stem Cells. 2016;34(4):820\u201331. https:\/\/doi.org\/10.1002\/stem.2320.","journal-title":"Stem Cells"},{"issue":"2","key":"3326_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00384-009-0818-8","volume":"25","author":"H Kn\u00fcpfer","year":"2010","unstructured":"Kn\u00fcpfer H, Preiss R. Serum interleukin-6 levels in colorectal cancer patients-a summary of published results. Int J Color Dis. 2010;25(2):135\u201340. https:\/\/doi.org\/10.1007\/s00384-009-0818-8.","journal-title":"Int J Color Dis"},{"issue":"10","key":"3326_CR12","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1038\/bjc.2013.174","volume":"108","author":"S Mitsunaga","year":"2013","unstructured":"Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Furuse J, Inagaki M, et al. Serum levels of IL-6 and IL-1\u03b2 can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 2013;108(10):2063\u20139. https:\/\/doi.org\/10.1038\/bjc.2013.174.","journal-title":"Br J Cancer"},{"issue":"8","key":"3326_CR13","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/cas.12187","volume":"104","author":"Y Makuuchi","year":"2013","unstructured":"Makuuchi Y, Honda K, Osaka Y, Kato K, Kojima T, Daiko H, et al. Soluble interleukin-6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy. Cancer Sci. 2013;104(8):1045\u201351. https:\/\/doi.org\/10.1111\/cas.12187.","journal-title":"Cancer Sci"},{"issue":"10","key":"3326_CR14","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ijsu.2012.11.007","volume":"10","author":"N Gupta","year":"2012","unstructured":"Gupta N, Goswami B, Mittal P. Effect of standard anthracycline based neoadjuvant chemotherapy on circulating levels of serum IL-6 in patients of locally advanced carcinoma breast\u2013a prospective study. Int J Surg. 2012;10(10):638\u201340. https:\/\/doi.org\/10.1016\/j.ijsu.2012.11.007.","journal-title":"Int J Surg"},{"issue":"11","key":"3326_CR15","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1182\/blood.V87.11.4510.bloodjournal87114510","volume":"87","author":"E Sporeno","year":"1996","unstructured":"Sporeno E, Savino R, Ciapponi L, Paonessa G, Cabibbo A, Lahm A, et al. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. Blood. 1996;87(11):4510\u20139. https:\/\/doi.org\/10.1182\/blood.V87.11.4510.bloodjournal87114510.","journal-title":"Blood"},{"issue":"12","key":"3326_CR16","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1139\/cjpp-2017-0413","volume":"95","author":"AH Fathy","year":"2017","unstructured":"Fathy AH, Bashandy MA, Bashandy SAE, Mansour AM, Elsadek B. Sequential analysis and staging of a diethylnitrosamine-induced hepatocellular carcinoma in male Wistar albino rat model. Can J Physiol Pharmacol. 2017;95(12):1462\u201372. https:\/\/doi.org\/10.1139\/cjpp-2017-0413.","journal-title":"Can J Physiol Pharmacol"},{"issue":"2","key":"3326_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.cld.2004.12.009","volume":"9","author":"FX Bosch","year":"2005","unstructured":"Bosch FX, Ribes J, Cl\u00e9ries R, D\u00edaz M. Epidemiology of hepatocellular carcinoma. Clinics in Liver Disease. 2005;9(2):191\u2013211. https:\/\/doi.org\/10.1016\/j.cld.2004.12.009.","journal-title":"Clinics in Liver Disease"},{"issue":"6","key":"3326_CR18","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"Cancer J Clin"},{"issue":"2","key":"3326_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12250-015-3599-y","volume":"30","author":"GG Luo","year":"2015","unstructured":"Luo GG, Ou J-h J. Oncogenic viruses and cancer. Virol Sin. 2015;30(2):83\u20134. https:\/\/doi.org\/10.1007\/s12250-015-3599-y.","journal-title":"Virol Sin"},{"issue":"9","key":"3326_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S2214-109X(16)30143-7","volume":"4","author":"M Plummer","year":"2016","unstructured":"Plummer M, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Global Health. 2016;4(9):609\u201316.","journal-title":"Lancet Global Health"},{"issue":"2","key":"3326_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. Cancer J Clin. 2015;65(2):87\u2013108. https:\/\/doi.org\/10.3322\/caac.21262.","journal-title":"Cancer J Clin"},{"issue":"1","key":"3326_CR22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.14218\/JCTH.2017.00031","volume":"6","author":"S Daher","year":"2018","unstructured":"Daher S, et al. Current and future treatment of hepatocellular carcinoma: an updated comprehensive review. J Clinical & Transl Hepatol. 2018;6(1):69\u201378.","journal-title":"J Clinical & Transl Hepatol"},{"key":"3326_CR23","first-page":"3026370","volume":"2017","author":"N Osafo","year":"2017","unstructured":"Osafo N, Mensah KB, Yeboah OK. Phytochemical and Pharmacological Review of Cryptolepis sanguinolenta (Lindl.) Schlechter. Adv Pharmacol Sci. 2017;2017:3026370\u201383.","journal-title":"Adv Pharmacol Sci"},{"issue":"10","key":"3326_CR24","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/ptr.2794","volume":"23","author":"OA Olajide","year":"2009","unstructured":"Olajide OA, Ajayi AM, Wright CW. Anti-inflammatory properties of cryptolepine. Phytother Res. 2009;23(10):1421\u20135. https:\/\/doi.org\/10.1002\/ptr.2794.","journal-title":"Phytother Res"},{"key":"3326_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejmech.2013.02.004","volume":"63","author":"OA Olajide","year":"2013","unstructured":"Olajide OA, Bhatia HS, de Oliveira ACP, Wright CW, Fiebich BL. Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-\u03baB and p38 MAPK inhibition. Eur J Med Chem. 2013;63:333\u20139. https:\/\/doi.org\/10.1016\/j.ejmech.2013.02.004.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"3326_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4314\/gmj.v44i1.68849","volume":"44","author":"K Bugyei","year":"2010","unstructured":"Bugyei K, Boye G, Addy M. Clinical efficacy of a tea-bag formulation of Cryptolepis sanguinolenta root in the treatment of acute uncomplicated falciparum malaria. Ghana Med J. 2010;44(1):3\u20139. https:\/\/doi.org\/10.4314\/gmj.v44i1.68849.","journal-title":"Ghana Med J"},{"issue":"2","key":"3326_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0378-8741(94)90071-X","volume":"44","author":"A Paulo","year":"1994","unstructured":"Paulo A, Pimentel M, Viegas S, Pires I, Duarte A, Cabrita J, et al. Cryptolepis sanguinolenta activity against diarrhoeal bacteria. J Ethnopharmacol. 1994;44(2):73\u20137. https:\/\/doi.org\/10.1016\/0378-8741(94)90071-X.","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"3326_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0378-8741(95)01323-7","volume":"50","author":"O Silva","year":"1996","unstructured":"Silva O, Duarte A, Cabrita J, Pimentel M, Diniz A, Gomes E. Antimicrobial activity of Guinea-Bissau traditional remedies. J Ethnopharmacol. 1996;50(1):55\u20139. https:\/\/doi.org\/10.1016\/0378-8741(95)01323-7.","journal-title":"J Ethnopharmacol"},{"issue":"7","key":"3326_CR29","first-page":"1140","volume":"6","author":"K Claude","year":"2012","unstructured":"Claude K, et al. Efficacy of Cryptolepis sanguinolenta root extract on slow-growing rifampicin-resistant mycobacterium tuberculosis. J Med Plants Res. 2012;6(7):1140\u20136.","journal-title":"J Med Plants Res"},{"issue":"12","key":"3326_CR30","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3390\/molecules21121758","volume":"21","author":"HC Pal","year":"2016","unstructured":"Pal HC, Katiyar SK. Cryptolepine, a plant alkaloid, inhibits the growth of non-melanoma skin cancer cells through inhibition of topoisomerase and induction of DNA damage. Molecules. 2016;21(12):1758. https:\/\/doi.org\/10.3390\/molecules21121758.","journal-title":"Molecules"},{"issue":"1","key":"3326_CR31","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1038\/s41598-017-01659-7","volume":"7","author":"HC Pal","year":"2017","unstructured":"Pal HC, Prasad R, Katiyar SK. Cryptolepine inhibits melanoma cell growth through coordinated changes in mitochondrial biogenesis, dynamics and metabolic tumour suppressor AMPK\u03b11\/2-LKB1. Sci Rep. 2017;7(1):1498\u2013502. https:\/\/doi.org\/10.1038\/s41598-017-01659-7.","journal-title":"Sci Rep"},{"issue":"1","key":"3326_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/toxsci\/kfj146","volume":"91","author":"H Zhu","year":"2006","unstructured":"Zhu H, Gooderham NJ. Mechanisms of induction of cell cycle arrest and cell death by cryptolepine in human lung adenocarcinoma A549 cells. Toxicol Sci. 2006;91(1):132\u20139. https:\/\/doi.org\/10.1093\/toxsci\/kfj146.","journal-title":"Toxicol Sci"},{"issue":"1","key":"3326_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nsb729","volume":"9","author":"JN Lisgarten","year":"2002","unstructured":"Lisgarten JN, Coll M, Portugal J, Wright CW, Aymami J. The antimalarial and cytotoxic drug cryptolepine intercalates into DNA at cytosine-cytosine sites. Nat Struct Mol Biol. 2002;9(1):57\u201368. https:\/\/doi.org\/10.1038\/nsb729.","journal-title":"Nat Struct Mol Biol"},{"issue":"47","key":"3326_CR34","doi-asserted-by":"publisher","first-page":"28309","DOI":"10.18632\/oncotarget.24875","volume":"9","author":"Q Jiang","year":"2018","unstructured":"Jiang Q, Sun Y, Guo Z, Chen R, Ma S, Fu M, et al. IL-23 enhances the malignant properties of hepatoma cells by attenuation of HNF4\u03b1. Oncotarget. 2018;9(47):28309\u201321. https:\/\/doi.org\/10.18632\/oncotarget.24875.","journal-title":"Oncotarget"},{"issue":"1","key":"3326_CR35","first-page":"1","volume":"8","author":"Y Yamamoto","year":"2018","unstructured":"Yamamoto Y, et al. Lipopolysaccharide shock reveals the immune function of indoleamine 2, 3-dioxygenase 2 through the regulation of IL-6\/stat3 signalling. Sci Rep. 2018;8(1):1\u201310.","journal-title":"Sci Rep"},{"issue":"2","key":"3326_CR36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","volume":"135","author":"C Tang","year":"2012","unstructured":"Tang C, Chen S, Qian H, Huang W. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012;135(2):112\u201324. https:\/\/doi.org\/10.1111\/j.1365-2567.2011.03522.x.","journal-title":"Immunology"},{"issue":"9","key":"3326_CR37","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1021\/ml100146z","volume":"1","author":"X Ren","year":"2010","unstructured":"Ren X, Duan L, He Q, Zhang Z, Zhou Y, Wu D, et al. Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signalling pathway. ACS Med Chem Lett. 2010;1(9):454\u20139. https:\/\/doi.org\/10.1021\/ml100146z.","journal-title":"ACS Med Chem Lett"},{"issue":"3","key":"3326_CR38","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1371\/journal.pntd.0002091","volume":"7","author":"AV Protasio","year":"2013","unstructured":"Protasio AV, Dunne DW, Berriman M. Comparative study of transcriptome profiles of mechanical-and skin-transformed Schistosoma mansoni schistosomula. PLoS Negl Trop Dis. 2013;7(3):2091\u2013102.","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"3326_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.yexmp.2017.08.002","volume":"103","author":"M Mbele","year":"2017","unstructured":"Mbele M, Hull R, Dlamini Z. African medicinal plants and their derivatives: current efforts towards potential anti-cancer drugs. Exp Mol Pathol. 2017;103(2):121\u201334. https:\/\/doi.org\/10.1016\/j.yexmp.2017.08.002.","journal-title":"Exp Mol Pathol"},{"key":"3326_CR40","doi-asserted-by":"crossref","unstructured":"Atanasov AG, et al. Natural products in drug discovery: Advances and opportunities. Nat Rev Drug Discov. 2021;20:200\u20132016.","DOI":"10.1038\/s41573-020-00114-z"},{"issue":"6","key":"3326_CR41","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/cells9061451","volume":"9","author":"S Bose","year":"2020","unstructured":"Bose S, Banerjee S, Mondal A, Chakraborty U, Pumarol J, Croley CR, et al. Targeting the JAK\/STAT signalling pathway using phytocompounds for cancer prevention and therapy. Cells. 2020;9(6):1451\u201391. https:\/\/doi.org\/10.3390\/cells9061451.","journal-title":"Cells"},{"issue":"23","key":"3326_CR42","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1158\/0008-5472.CAN-15-0816","volume":"75","author":"AL Oei","year":"2015","unstructured":"Oei AL, van Leeuwen CM, ten Cate R, Rodermond HM, Buist MR, Stalpers LJA, et al. Hyperthermia selectively targets human papillomavirus in cervical tumours via p53-dependent apoptosis. Cancer Res. 2015;75(23):5120\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0816.","journal-title":"Cancer Res"},{"issue":"9","key":"3326_CR43","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1136\/gut.2005.066514","volume":"54","author":"A Conlin","year":"2005","unstructured":"Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut. 2005;54(9):1283\u20136. https:\/\/doi.org\/10.1136\/gut.2005.066514.","journal-title":"Gut"},{"key":"3326_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.pharmthera.2015.05.008","volume":"152","author":"C Vizca\u00edno","year":"2015","unstructured":"Vizca\u00edno C, Mansilla S, Portugal J. Sp1 transcription factor: a long-standing target in cancer chemotherapy. Pharmacol Ther. 2015;152:111\u201324. https:\/\/doi.org\/10.1016\/j.pharmthera.2015.05.008.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"3326_CR45","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1182\/blood-2014-08-593343","volume":"125","author":"M Meinders","year":"2015","unstructured":"Meinders M, Kulu DI, van de Werken HJG, Hoogenboezem M, Janssen H, Brouwer RWW, et al. Sp1\/Sp3 transcription factors regulate hallmarks of megakaryocyte maturation and platelet formation and function. Blood. 2015;125(12):1957\u201367. https:\/\/doi.org\/10.1182\/blood-2014-08-593343.","journal-title":"Blood"},{"issue":"9","key":"3326_CR46","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1002\/ijc.24563","volume":"125","author":"JY Chuang","year":"2009","unstructured":"Chuang JY, Wu CH, Lai MD, Chang WC, Hung JJ. Overexpression of Sp1 leads to p53-dependent apoptosis in cancer cells. Int J Cancer. 2009;125(9):2066\u201376. https:\/\/doi.org\/10.1002\/ijc.24563.","journal-title":"Int J Cancer"},{"issue":"1","key":"3326_CR47","doi-asserted-by":"publisher","first-page":"12189","DOI":"10.1038\/s41598-017-12414-3","volume":"7","author":"H Enomoto","year":"2017","unstructured":"Enomoto H, Tao L, Eguchi R, Sato A, Honda M, Kaneko S, et al. The in vivo antitumor effects of type I-interferon against hepatocellular carcinoma: the suppression of tumour cell growth and angiogenesis. Sci Rep. 2017;7(1):12189. https:\/\/doi.org\/10.1038\/s41598-017-12414-3.","journal-title":"Sci Rep"},{"issue":"2","key":"3326_CR48","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.immuni.2011.02.006","volume":"34","author":"G Guarda","year":"2011","unstructured":"Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, F\u00f6rster I, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity. 2011;34(2):213\u201323. https:\/\/doi.org\/10.1016\/j.immuni.2011.02.006.","journal-title":"Immunity"},{"key":"3326_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/4828936","volume":"2017","author":"Y Xia","year":"2017","unstructured":"Xia Y, Cheng X, Blossey CK, Wisskirchen K, Esser K, Protzer U. Secreted interferon-inducible factors restrict hepatitis B and C virus entry in vitro. J Immunol Res. 2017;2017:1\u201312. https:\/\/doi.org\/10.1155\/2017\/4828936.","journal-title":"J Immunol Res"},{"issue":"14","key":"3326_CR50","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-17-3008","volume":"24","author":"Z Ye","year":"2018","unstructured":"Ye Z, Dong H, Li Y, Ma T, Huang H, Leong HS, et al. Prevalent homozygous deletions of type I interferon and defensin genes in human cancers associated with immunotherapy resistance. Clin Cancer Res. 2018;24(14):3299\u2013308. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3008.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3326_CR51","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13578-015-0056-4","volume":"5","author":"H Zhang","year":"2015","unstructured":"Zhang H, Sun S-C. NF-\u03baB in inflammation and renal diseases. Cell Bioscience. 2015;5(1):63. https:\/\/doi.org\/10.1186\/s13578-015-0056-4.","journal-title":"Cell Bioscience"},{"key":"3326_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/459723","volume":"2013","author":"OA Olajide","year":"2013","unstructured":"Olajide OA, Bhatia HS, de Oliveira ACP, Wright CW, Fiebich BL. Inhibition of neuroinflammation in LPS-activated microglia by cryptolepine. Evid Based Complement Alternat Med. 2013;2013:1\u201310. https:\/\/doi.org\/10.1155\/2013\/459723.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"1","key":"3326_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-017-0001-6","volume":"3","author":"H Chen","year":"2018","unstructured":"Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduction targeted therapy. 2018;3(1):1\u20137.","journal-title":"Signal Transduction targeted therapy"},{"issue":"3","key":"3326_CR54","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/bies.201500134","volume":"38","author":"CM Koh","year":"2016","unstructured":"Koh CM, Sab\u00f2 A, Guccione E. Targeting MYC in cancer therapy: RNA processing offers new opportunities. Bioessays. 2016;38(3):266\u201375. https:\/\/doi.org\/10.1002\/bies.201500134.","journal-title":"Bioessays"},{"issue":"1","key":"3326_CR55","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/sj.onc.1205016","volume":"21","author":"F Hong","year":"2002","unstructured":"Hong F, Kim WH, Tian Z, Jaruga B, Ishac E, Shen X, et al. Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-xL proteins. Oncogene. 2002;21(1):32\u201344. https:\/\/doi.org\/10.1038\/sj.onc.1205016.","journal-title":"Oncogene"},{"issue":"2","key":"3326_CR56","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4161\/15384101.2014.977112","volume":"14","author":"X Sun","year":"2015","unstructured":"Sun X, Zhang J, Hou Z, Han Q, Zhang C, Tian Z. miR-146a is directly regulated by STAT3 in human hepatocellular carcinoma cells and involved in anti-tumour immune suppression. Cell Cycle. 2015;14(2):243\u201352. https:\/\/doi.org\/10.4161\/15384101.2014.977112.","journal-title":"Cell Cycle"},{"issue":"6","key":"3326_CR57","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.3390\/ijms19061787","volume":"19","author":"F Laudisi","year":"2018","unstructured":"Laudisi F, Cherubini F, Monteleone G, Stolfi C. STAT3 interactors as potential therapeutic targets for cancer treatment. Int J Mol Sci. 2018;19(6):1787. https:\/\/doi.org\/10.3390\/ijms19061787.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3326_CR58","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s13046-019-1303-z","volume":"38","author":"S Lin","year":"2019","unstructured":"Lin S, Yang L, Yao Y, Xu L, Xiang Y, Zhao H, et al. Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy. J Exp Clin Cancer Res. 2019;38(1):293. https:\/\/doi.org\/10.1186\/s13046-019-1303-z.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"3326_CR59","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1016\/j.bbadis.2018.10.004","volume":"1864","author":"M Zang","year":"2018","unstructured":"Zang M, et al. IL-23 production of liver inflammatory macrophages to damaged hepatocytes promotes hepatocellular carcinoma development after chronic hepatitis B virus infection. Biochimica et Biophysica Acta (BBA)-Molecular Basis Dis. 2018;1864(12):3759\u201370.","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Basis Dis"},{"issue":"11","key":"3326_CR60","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/s41419-018-1139-z","volume":"9","author":"W Zhang","year":"2018","unstructured":"Zhang W, Yu W, Cai G, Zhu J, Zhang C, Li S, et al. A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy. Cell Death Dis. 2018;9(11):1098. https:\/\/doi.org\/10.1038\/s41419-018-1139-z.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3326_CR61","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00262-017-2057-0","volume":"67","author":"MW Khan","year":"2018","unstructured":"Khan MW, Saadalla A, Ewida AH, al-Katranji K, al-Saoudi G, Giaccone ZT, et al. The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer. Cancer Immunol. 2018;67(1):13\u201323. https:\/\/doi.org\/10.1007\/s00262-017-2057-0.","journal-title":"Cancer Immunol"},{"issue":"1","key":"3326_CR62","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1124\/jpet.110.165498","volume":"334","author":"SM-L Tan","year":"2010","unstructured":"Tan SM-L, Li F, Rajendran P, Kumar AP, Hui KM, Sethi G. Identification of \u03b2-escin as a novel inhibitor of signal transducer and activator of transcription 3\/Janus-activated kinase 2 signalling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. J Pharmacol Exp Ther. 2010;334(1):285\u201393. https:\/\/doi.org\/10.1124\/jpet.110.165498.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"3326_CR63","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.canlet.2009.12.003","volume":"292","author":"F Li","year":"2010","unstructured":"Li F, Fernandez PP, Rajendran P, Hui KM, Sethi G. Diosgenin, a steroidal saponin, inhibits STAT3 signalling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett. 2010;292(2):197\u2013207. https:\/\/doi.org\/10.1016\/j.canlet.2009.12.003.","journal-title":"Cancer Lett"},{"issue":"48","key":"3326_CR64","first-page":"1","volume":"9","author":"C-Y Loh","year":"2019","unstructured":"Loh C-Y, et al. Signal transducer and activator of transcription (STATs) proteins in cancer and inflammation: functions and therapeutic implication. Front Oncol. 2019;9(48):1\u201315.","journal-title":"Front Oncol"},{"issue":"1","key":"3326_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-47707-2","volume":"9","author":"J Gyamfi","year":"2019","unstructured":"Gyamfi J, et al. Niclosamide reverses adipocyte induced epithelial-mesenchymal transition in breast cancer cells via suppression of the interleukin-6\/STAT3 signalling axis. Sci Rep. 2019;9(1):1\u201314.","journal-title":"Sci Rep"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-021-03326-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-021-03326-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-021-03326-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T10:57:39Z","timestamp":1672311459000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-021-03326-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,2]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3326"],"URL":"https:\/\/doi.org\/10.1186\/s12906-021-03326-x","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,2]]},"assertion":[{"value":"14 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"161"}}